EP3820499A4 - Tissue-specific wnt signal enhancing molecules and uses - Google Patents

Tissue-specific wnt signal enhancing molecules and uses Download PDF

Info

Publication number
EP3820499A4
EP3820499A4 EP19833402.1A EP19833402A EP3820499A4 EP 3820499 A4 EP3820499 A4 EP 3820499A4 EP 19833402 A EP19833402 A EP 19833402A EP 3820499 A4 EP3820499 A4 EP 3820499A4
Authority
EP
European Patent Office
Prior art keywords
tissue
wnt signal
signal enhancing
enhancing molecules
specific wnt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19833402.1A
Other languages
German (de)
French (fr)
Other versions
EP3820499A1 (en
Inventor
Zhengjian ZHANG
Yang Li
Wen-Chen Yeh
Tom Zhiye YUAN
Helene Baribault
Kuo-pao Lai (jimmy)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surrozen Operating Inc
Original Assignee
Surrozen Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surrozen Operating Inc filed Critical Surrozen Operating Inc
Publication of EP3820499A1 publication Critical patent/EP3820499A1/en
Publication of EP3820499A4 publication Critical patent/EP3820499A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19833402.1A 2018-07-09 2019-07-09 Tissue-specific wnt signal enhancing molecules and uses Pending EP3820499A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862695509P 2018-07-09 2018-07-09
US201862770026P 2018-11-20 2018-11-20
US201962822731P 2019-03-22 2019-03-22
PCT/US2019/041067 WO2020014271A1 (en) 2018-07-09 2019-07-09 Tissue-specific wnt signal enhancing molecules and uses

Publications (2)

Publication Number Publication Date
EP3820499A1 EP3820499A1 (en) 2021-05-19
EP3820499A4 true EP3820499A4 (en) 2022-07-13

Family

ID=69142996

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19833402.1A Pending EP3820499A4 (en) 2018-07-09 2019-07-09 Tissue-specific wnt signal enhancing molecules and uses

Country Status (7)

Country Link
US (1) US20210380678A1 (en)
EP (1) EP3820499A4 (en)
JP (1) JP2021530223A (en)
CN (1) CN112654363A (en)
AU (1) AU2019301633A1 (en)
CA (1) CA3104868A1 (en)
WO (1) WO2020014271A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7305543B2 (en) 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド Tissue-specific Wnt signal enhancing molecules and uses thereof
CN111010866A (en) 2017-05-24 2020-04-14 潘迪恩治疗公司 Targeted immune tolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019126398A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
WO2019126399A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-frizzled antibodies and methods of use
JP7317016B2 (en) 2017-12-19 2023-07-28 スロゼン オペレーティング， インコーポレイテッド Anti-LRP5/6 Antibodies and Methods of Use
JP2022533702A (en) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド MAdCAM-targeted immune tolerance
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
EP4107189A4 (en) * 2020-02-21 2024-07-03 Pandion Operations Inc Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
US20230138045A1 (en) * 2020-02-24 2023-05-04 Surrozen Operating, Inc. Wnt super agonists
EP4165171A1 (en) 2020-06-12 2023-04-19 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
CN112426526B (en) * 2021-01-25 2021-04-06 北京达熙生物科技有限公司 Preparation method of NK (natural killer) cells and application of NK cells in treatment of cancers
CN118076387A (en) * 2021-10-08 2024-05-24 艾贝乐医药科技有限公司 Multispecific antibodies targeting CDH 17-expressing tumors and methods of making and using the same
WO2023246570A1 (en) * 2022-06-20 2023-12-28 广东克冠达医药科技有限公司 Interleukin-9 antibody and use thereof
WO2023250291A2 (en) * 2022-06-21 2023-12-28 Surrozen Operating, Inc. Modulation of wnt signalling in corneal disorders
WO2024092016A1 (en) * 2022-10-26 2024-05-02 Research Development Foundation Cell targeting constructs and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2014023709A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
WO2015164392A2 (en) * 2014-04-21 2015-10-29 Stemcentrx, Inc. Novel antii-rnf43 antibodies and methods of use
WO2017069628A2 (en) * 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
WO2016068803A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
DK3386534T3 (en) * 2015-12-08 2020-11-30 Regeneron Pharma Compositions and methods for internalizing enzymes
CA3044574A1 (en) * 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
JP7305543B2 (en) * 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド Tissue-specific Wnt signal enhancing molecules and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2014023709A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
WO2015164392A2 (en) * 2014-04-21 2015-10-29 Stemcentrx, Inc. Novel antii-rnf43 antibodies and methods of use
WO2017069628A2 (en) * 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JACQUELYN O RUSSELL ET AL: "Annual Review of Pathology: Mechanisms of Disease Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology", ANNU. REV. PATHOL. MECH. DIS, 10 November 2017 (2017-11-10), pages 351 - 78, XP055698055, Retrieved from the Internet <URL:https://www.annualreviews.org/doi/pdf/10.1146/annurev-pathol-020117-044010> [retrieved on 20200525], DOI: 10.1146/annurev-pathol-020117- *
PEREZ DE LA LASTRA ET AL: "Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP)", IMMUNOLOGY, vol. 96, no. 4, 1 April 1999 (1999-04-01), GB, pages 663 - 670, XP055572134, ISSN: 0019-2805, DOI: 10.1046/j.1365-2567.1999.00732.x *
See also references of WO2020014271A1 *
SHILPI SATISH ET AL: "Drug targeting strategies for liver cancer and other liver diseases", MOJ DRUG DESIGN DEVELOPMENT & THERAPY, vol. 2, no. 4, 3 July 2018 (2018-07-03), pages 171 - 177, XP055925577, Retrieved from the Internet <URL:https://medcraveonline.com/MOJDDT/MOJDDT-02-00044.pdf> *
TAO GUO-ZHONG ET AL: "Wnt/[beta]-Catenin Signaling Protects Mouse Liver against Oxidative Stress-induced Apoptosis through the Inhibition of Forkhead Transcription Factor FoxO3", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 24, 25 April 2013 (2013-04-25), US, pages 17214 - 17224, XP055925579, ISSN: 0021-9258, Retrieved from the Internet <URL:https://www.jbc.org/action/showPdf?pii=S0021-9258(20)45867-3> DOI: 10.1074/jbc.M112.445965 *
ZHANG ZHENGJIAN ET AL: "Tissue-targeted R-spondin mimetics for liver regeneration", SCIENTIFIC REPORTS, vol. 10, no. 1, 18 August 2020 (2020-08-18), XP055926092, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435267/pdf/41598_2020_Article_70912.pdf> DOI: 10.1038/s41598-020-70912-3 *

Also Published As

Publication number Publication date
AU2019301633A1 (en) 2021-01-28
US20210380678A1 (en) 2021-12-09
JP2021530223A (en) 2021-11-11
WO2020014271A1 (en) 2020-01-16
EP3820499A1 (en) 2021-05-19
CN112654363A (en) 2021-04-13
CA3104868A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
EP3820499A4 (en) Tissue-specific wnt signal enhancing molecules and uses
EP3574019A4 (en) Tissue-specific wnt signal enhancing molecules and uses thereof
EP3732201A4 (en) Wnt surrogate molecules and uses thereof
EP3625358A4 (en) Biomarkers and uses thereof
EP3714298A4 (en) Waveguide display and display element with novel grating configuration
EP3280432B8 (en) De novo binding domain containing polypeptides and uses thereof
EP3333192A4 (en) Antibody against glypican-3 and application thereof
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
EP3487299A4 (en) Multimeric gitr binding molecules and uses thereof
EP3604334A4 (en) Antibody binding specifically to muc1 and use thereof
EP3752537A4 (en) Multivalent binding molecules activating wnt signaling and uses thereof
EP3717944A4 (en) Waveguide and sensor based on same
EP3849608A4 (en) Novel lilrb4 antibodies and uses thereof
EP3426298A4 (en) Ilt7 binding molecules and methods of using the same
EP3377610A4 (en) Ratiometric biosensors and non-geometrically modulated fret
EP3589290A4 (en) Translatable molecules and synthesis thereof
EP3589640A4 (en) Protein purification with protein l
EP3820906A4 (en) Multi-specific wnt surrogate molecules and uses thereof
EP3867405A4 (en) Epigenetic biomarker and uses therefor
EP3525824A4 (en) Long acting multi-specific molecules and related methods
EP3794027A4 (en) Optimized gp41-binding molecules and uses thereof
EP3997230A4 (en) Claudin-6 binding molecules and uses thereof
EP3740496A4 (en) Proteinaceous molecules and uses therefor
EP3758738A4 (en) Modified plyss2 lysins and uses thereof
EP3781204A4 (en) Binding molecules

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048447

Country of ref document: HK

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SURROZEN OPERATING, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20220610

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/16 20060101ALI20220603BHEP

Ipc: C07K 16/28 20060101ALI20220603BHEP

Ipc: C07K 16/18 20060101ALI20220603BHEP

Ipc: A61K 38/17 20060101AFI20220603BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516